Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QEL-001 in HLA-A2-mismatched Liver Transplant Recipients
2024-516193-30-01Phase 2Authorised
- Sponsor
- Quell Therapeutics
- Start
- Sep 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of QEL-001 in Hepatic transplant rejection (LTR), sponsored by Quell Therapeutics. Primary endpoints: Incidence of protocol-defined dose-limiting toxicities (DLTs) and Incidence and severity of treatment-emergent adverse events (TEAEs) including serious adverse events (SAEs). Planned start Sep 2024; status: authorised.
02
Drugs
QEL-001
03
Conditions
Hepatic transplant rejection (LTR)
Beyond the preview
Go deeper on 2024-516193-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516193-30-01.